Method for use of oligonucleotide therapeutics

Abstract

It has now been discovered that oligonucleotides which tend to form multimeric aggregates have greater toxicity in the aggregate form than in monomeric form. Thus, administration of a therapeutic oligonucleotide that tends to form multimeric aggregates is suitably preceding by a treatment to convert substantially all of the therapeutic oligonucleotide to a monomeric form or to substantially prevent the formation of multimeric aggregates; and then administering the composition in which substantially all of the therapeutic oligonucleotide is in monomeric form to a mammal in need of therapy provided by the oligonucleotide. The composition can be treated by heating, preferably no more than 24 hours prior to administration, or using chemical species such as mannitol or sucrose which disrupt aggregates.

Dependencies are inferred from the claim text.